At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
TRC105 +1 moredrug
Likely dose
TRC105 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab
In Brief
A Phase 2 clinical trial evaluating TRC105 and Bevacizumab for Glioblastoma and Glioblastoma Multiforme. Completed, enrolled 22 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma, Glioblastoma Multiforme
CountriesUnited States
CollaboratorsThe Cleveland Clinic, Case Comprehensive Cancer Center
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartMay 2012
Primary CompletionJun 2015
TodayJul 2026
First PostedMar 28, 2012
Enrollment StartMay 1, 2012
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 14.3 years ago
Interventions
TRC105drug
10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
Bevacizumabdrug
IV